Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the β2/β2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.
1. A peptide-based inhibitor of the proteasome β2/β21 site comprising the structure:
(Y)-(X4)-X3-X2-X1 (SEQ ID NO:2),
wherein X1 is Phe residue or an aminosubstituted phenylalanine derivative wherein said residue or derivative comprises a carboxy-terminal epoxyketone or vinyl sulfone warhead; X2 is Leu or Ser; X3 is Leu, Val, Ser, Arg, His, Lys, Phe or an aminosubstituted phenylalanine derivative; X4 is present or absent and when present is Phe; Y is present or absent and when present is a capping group; and wherein each aminosubstituted phenylalanine derivative has a structure:
wherein X is independently N, C—NH 2 , or C—CH 2 —NH 2 .
2. The peptide-based inhibitor of claim 1 , wherein the capping group is a label.
3. The peptide-based inhibitor of claim 2 , wherein the label comprises a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene fluorophore, a fluoroscein, a rhodamine dye or biotin.
4. A pharmaceutical composition comprising the peptide-based inhibitor of claim 1 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , further comprising an inhibitor of the proteasome β5/β5i site.
6. A method for inhibiting the activity of the β2/β2i site of a proteasome comprising contacting a proteasome with a peptide-based inhibitor of claim 1 so that activity of the proteasome β2/β2i site is inhibited.
7. A method for treating multiple myeloma, organ graft rejection, lupus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, parasitic disease, chronic obstructive pulmonary disease, psoriasis, bronchitis, emphysema or cystic fibrosis comprising administering to a subject in need of treatment an effective amount of the pharmaceutical composition of claim 4 thereby treating the multiple myeloma, organ graft rejection, lupus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, parasitic disease, chronic obstructive pulmonary disease, psoriasis, bronchitis, emphysema or cystic fibrosis.
8. The method of claim 7 , further comprising administering an inhibitor of the proteasome β5/β5i site.
9. A method for producing the peptide-based inhibitor of claim 1 , comprising
(a) protecting amine groups of arginine or an aminosubstituted phenylalanine derivative; wherein each aminosubstituted phenylalanine has a structure:
wherein X is independently N, C—H 2 , or C—CH 2 —NH 2 ,
(b) introducing an epoxyketone or vinyl sulfone warhead onto the arginine or aminosubstituted phenylalanine derivative, and
(c) attaching a proteasomal β2/β2i site-selective oligopeptide to the alpha amino-group of the arginine or aminosubstituted phenylalanine derivative so that a peptide-based inhibitor is produced.
10. A peptide-based inhibitor of the proteasome β2/β2i site comprising the structure:
(Y)-(X4)-X3-X2-X1 (SEQ ID NO:2),
wherein X1 is an Arg or Phe residue or an aminosubstituted phenylalanine derivative wherein said residue or derivative comprises a carboxy-terminal epoxyketone or vinyl sulfone warhead; X2 is Leu or Ser; X3 is Leu, Val, Ser, Arg, His, Lys, Phe or an aminosubstituted phenylalanine derivative; X4 is Phe; Y is present or absent and when present is a capping group; and wherein each aminosubstituted phenylalanine derivative has a structure:
wherein X is independently N, C—NH 2 , or C—CH 2 —NH 2 .
11. The peptide-based inhibitor of claim 10 , wherein the capping group is a label.
12. The peptide-based inhibitor of claim 11 , wherein the label comprises a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene fluorophore, a fluoroscein, a rhodamine dye or biotin.
13. A pharmaceutical composition comprising the peptide-based inhibitor of claim 10 and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , further comprising an inhibitor of the proteasome β5/β5i site.
15. A peptide-based inhibitor of the proteasome β2/β2i site comprising the structure:
(Y)-(X4)-X3-X2-X1 (SEQ ID NO:2),
wherein X1 is an Arg or Phe residue or an aminosubstituted phenylalanine derivative wherein said residue or derivative comprises a carboxy-terminal epoxyketone or vinyl sulfone warhead; X2 is Leu or Ser; X3 is Leu, Val, Ser, Arg, His, Lys, Phe or an aminosubstituted phenylalanine derivative; X4 is present or absent and when present is Phe; Y is present or absent and when present is a capping group selected from the group of an N-(3-hydroxy-2-methylbenzoyl) group, an acetyl group, a benzoyl group, an azido group, or a label; and wherein each aminosubstituted phenylalanine derivative has a structure:
wherein X is independently N, C—NH 2 , or C—CH 2 —NH 2 .
16. The peptide-based inhibitor of claim 15 , wherein the label comprises a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene fluorophore, a fluoroscein, a rhodamine dye or biotin.
17. A pharmaceutical composition comprising the peptide-based inhibitor of claim 15 and a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 17 , further comprising an inhibitor of the proteasome β5/β5i site.